Jae Park, MD

An oncologist specializing in the treatment of patients with B-ALL discusses the study design, efficacy, safety, and two-year updated results of the phase I/II ZUMA-3 study evaluating brexucabtagene autoleucel in adult patients with R/R B-ALL.

Jae Park, MD, shares an overview of available therapeutic options for patients with R/R B-ALL.

Jae Park, MD, discusses dosing strategies utilized in the phase 1/2 FELIX trial in relapsed/refractory acute lymphoblastic leukemia.

Closing thoughts on advances and future perspectives in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Expectations regarding where novel therapies such as CAR T-cell therapies will fit into B-cell acute lymphoblastic leukemia treatment algorithms as data from clinical trials continue to evolve.

Discussion on the role of transplantation in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The significance of having novel therapies and molecular tests available to help guide treatment decisions for patients with B-cell acute lymphoblastic leukemia, and recommendations on how to increase the uptake of MRD testing into routine clinical practice.

When to test for measurable residual disease in B-cell acute lymphoblastic leukemia, and what to keep in mind when selecting a testing method to help assess MRD.

An overview of adverse events commonly associated with CAR T-cell therapies in relapsed/refractory B-cell acute lymphoblastic leukemia.

Recommendations for sequencing CAR T-cell therapies and other key therapies in patients with B-cell acute lymphoblastic leukemia.

Implications of the ZUMA-3 clinical trial of anti-CD19 CAR T-cell therapy for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Background information regarding the manifestation and prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Jae Park, MD, hematologist oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL).

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Memorial Hospital, discusses vemurafenib in hairy cell leukemia.